Direct Targeting <i>KRAS</i> Mutation in Non-Small Cell Lung Cancer: Focus on Resistance

Direct Targeting <i>KRAS</i> Mutation in Non-Small Cell Lung Cancer: Focus on Resistance

KRAS is the most frequently mutated oncogene in non-small cell lung cancers (NSCLC), with a frequency of around 30%, and encoding a GTPAse that cycles between active form (GTP-bound) to inactive form (GDP-bound). The <i>KRAS</i> mutations favor the active form with inhibition of GTPAse a...

Full description

Bibliographic Details
Main Authors: Damien Reita, Lucile Pabst, Erwan Pencreach, Eric Guérin, Laurent Dano, Valérie Rimelen, Anne-Claire Voegeli, Laurent Vallat, Céline Mascaux, Michèle Beau-Faller
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Cancers
Subjects:
<i>KRAS</i> mutations
non-small cell lung cancer
<i>KRAS</i> G12C inhibitors
resistance mechanisms
phenotypic changes
Online Access:https://www.mdpi.com/2072-6694/14/5/1321

Internet

https://www.mdpi.com/2072-6694/14/5/1321

Similar Items